Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).
B. Lan, Ye-Hui Shi, Xi-Ying Shao et al.· The Lancet· 0 citations
Importance
Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer.
Objective
To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...
Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al.· Journal of the American Medi...· 1 citation
Background Cardiovascular disease (CVD) remains a major complication contributing to morbidity and mortality among individuals with diabetes. Different glycemic biomarkers reflect distinct aspects of glucose metabolism, but their associations with prevalent CVD across different diabetic populations remain incompletely...
Li-Hong Zhang, Meng-Zhen Liu, Yu Zhang et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.